Trial Profile
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Hairy Cell Leukemia (HCL).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Moxetumomab pasudotox (Primary)
- Indications Hairy cell leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors MedImmune
- 19 Feb 2020 Results (n=123) of a pooled analysis of data from 2 trials (Study 1001 and Study 1053) assessing pharmacokinetics of moxetumomab pasudotox in adults with relapsed or refractory Hairy Cell Leukemia published in the British Journal of Clinical Pharmacology.
- 04 Jun 2019 Results assessing pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfk presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Results of population PK model by using pooled data from two studies including this study presented at the 54th Annual Meeting of the American Society of Clinical Oncology.